Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amemuclonal anti-EGFR antibody plus anti-PD-1 antibody and FOLFIRI versus anti-EGFR antibody or cetuximab plus FOLFIRI in RAS wild-type advanced colorectal cancer
CTR20222853Phase 2Active
- Sponsor
- Cell-Far Biotech
- Start
- Nov 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ametumumab, toripalimab, cetuximab, irinotecan, folinic acid in colorectal cancer (CRC), colorectal adenocarcinoma, sponsored by Cell-Far Biotech. Started Nov 2022; status: active.
02
Drugs
ametumumabtoripalimabcetuximabirinotecanfolinic acid
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20222853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222853.